Business
Nanobiotix closes USD 100m global offering to advance Nanoprimer platform
Paris-based Nanobiotix (Euronext: NANO; Nasdaq: NBTX), a late-stage clinical biotechnology company developing physics-based cancer therapies, has closed a...
Cartesian Therapeutics secures USD 150m in credit to fund BCMA CAR-T ahead of Phase III data
Frederick, Maryland-based Cartesian Therapeutics (Nasdaq: RNAC) has announced a non-dilutive credit facility of up to USD 150 million with K2 HealthVentures...
Parabilis seeks Nasdaq listing with USD 75m strategic investment from Regeneron
Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company whose lead oncology asset has generated a 74% objective response rate in...
TransThera, Allist to test out AXL/FLT3 inhibitor with EGFRi against NSCLC
TransThera Sciences (Nanjing), Inc. (HKEX: 2617) and Shanghai Allist Pharmaceuticals Co., Ltd. (SSE: 688578) have entered a clinical trial collaboration and...
Incyte expands molecular AI collaboration with Genesis in USD 1b+ deal
Incyte (Nasdaq: INCY) has expanded its molecular AI collaboration with Genesis Molecular AI, committing USD 120 million upfront to broaden deployment of...
Lilly pushes into vaccines via USD 3.8b in three separate acquisitions
Eli Lilly (NYSE: LLY) has announced agreements to acquire three private companies — Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc. — in...
HanchorBio moving towards circa USD 140m Taiwan Innovation Board listing
HanchorBio Inc. (TPEx: 7827), a Taiwan-headquartered clinical-stage immunotherapy company with offices in Shanghai and the San Francisco Bay Area, priced...
Ingenia Therapeutics gains Korea Exchange approval for public listing amid Merck partnership
Ingenia Therapeutics, a Watertown, Massachusetts-based biotechnology company whose lead ophthalmology antibody is being developed by Merck, received...
Whitehawk Therapeutics licenses Hangzhou DAC's CPT113 linker-payload for up to five ADC programs
Whitehawk Therapeutics (Nasdaq: WHWK) has entered an option agreement with China's Hangzhou DAC Biotech to access the CPT113 linker-payload technology...
Oorja Bio emerges from stealth mode with USD 30m Series A to advance pulmonary fibrosis peptide ORJ-001
Oorja Bio, a Houston-based clinical-stage biopharmaceutical company, has launched with USD 30 million in Series A financing from founding investor Westlake...
Gilead finalizes up to USD 5b acquisition of Tubulis' ADC platform
Gilead Sciences (Nasdaq: GILD) has completed its acquisition of Tubulis GmbH, a clinical-stage biotechnology company based in Munich, Germany, adding a...
Imperagen closes GBP 5 million seed round for quantum-powered enzyme engineering
Imperagen closes GBP 5 million seed round to scale enzyme engineering platform
PharmAla Biotech grants Jupiter Neuro US rights to ALA-002 MDMA therapeutic for USD 100m
PharmAla Biotech (CSE: MDMA; OTCQB: MDXXF, Toronto) has signed a term sheet to grant Jupiter Neurosciences (Nasdaq: JUNS, Jupiter, Florida) exclusive,...
Eli Lilly adds non-viral genetic meds platform via USD 202m Engage Bio acquisition
Eli Lilly has acquired San Carlos, California-based Engage Biologics Inc. for up to USD 202 million in cash, adding the company's Tethosome non-viral DNA...
Forlong Bio secures USD 17.5m in Pre-B funding for cytokine pipeline advancement
Suzhou-based Forlong Biotechnology has closed a Series Pre-B financing round of approximately RMB 120 million (USD 17.5 million) to advance its IL-15 and...
The AllSci Brief
Systematic R&D and deal news. Daily.